Published in Mol Cell Biol on July 01, 2006
Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest (2007) 5.19
Endothelin-1 induces alveolar epithelial-mesenchymal transition through endothelin type A receptor-mediated production of TGF-beta1. Am J Respir Cell Mol Biol (2007) 2.50
Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels. Nat Commun (2013) 2.31
Jun N-terminal kinase 1 regulates epithelial-to-mesenchymal transition induced by TGF-beta1. J Cell Sci (2008) 1.60
Fibrosis in connective tissue disease: the role of the myofibroblast and fibroblast-epithelial cell interactions. Arthritis Res Ther (2007) 1.47
Retracted GSK-3beta in mouse fibroblasts controls wound healing and fibrosis through an endothelin-1-dependent mechanism. J Clin Invest (2008) 1.46
Transcriptome analysis reveals differential splicing events in IPF lung tissue. PLoS One (2014) 1.45
siRNA-targeting transforming growth factor-β type I receptor reduces wound scarring and extracellular matrix deposition of scar tissue. J Invest Dermatol (2014) 1.44
SPARC suppresses apoptosis of idiopathic pulmonary fibrosis fibroblasts through constitutive activation of beta-catenin. J Biol Chem (2010) 1.29
c-Jun N-terminal kinase 1 is required for the development of pulmonary fibrosis. Am J Respir Cell Mol Biol (2008) 1.26
Myofibroblasts: trust your heart and let fate decide. J Mol Cell Cardiol (2013) 1.25
Cardiac Fibrosis: The Fibroblast Awakens. Circ Res (2016) 1.21
Endothelin-1 and transforming growth factor-beta1 independently induce fibroblast resistance to apoptosis via AKT activation. Am J Respir Cell Mol Biol (2009) 1.20
FAK is required for TGFbeta-induced JNK phosphorylation in fibroblasts: implications for acquisition of a matrix-remodeling phenotype. Mol Biol Cell (2007) 1.19
The role of connective tissue growth factor (CTGF/CCN2) in skeletogenesis. Crit Rev Eukaryot Gene Expr (2011) 1.11
c-Jun N-terminal kinase 1 promotes transforming growth factor-β1-induced epithelial-to-mesenchymal transition via control of linker phosphorylation and transcriptional activity of Smad3. Am J Respir Cell Mol Biol (2010) 1.11
Inhibition of focal adhesion kinase prevents experimental lung fibrosis and myofibroblast formation. Arthritis Rheum (2012) 1.06
Cardiac fibroblast in development and wound healing. J Mol Cell Cardiol (2014) 1.05
Endoglin promotes TGF-β/Smad1 signaling in scleroderma fibroblasts. J Cell Physiol (2011) 1.03
A novel role of endothelin-1 in linking Toll-like receptor 7-mediated inflammation to fibrosis in congenital heart block. J Biol Chem (2011) 1.03
Rac1 expression by fibroblasts is required for tissue repair in vivo. Am J Pathol (2009) 1.03
Survivin expression induced by endothelin-1 promotes myofibroblast resistance to apoptosis. Int J Biochem Cell Biol (2011) 0.99
Mechanical tension increases CCN2/CTGF expression and proliferation in gingival fibroblasts via a TGFβ-dependent mechanism. PLoS One (2011) 0.97
Genomic differences distinguish the myofibroblast phenotype of distal lung fibroblasts from airway fibroblasts. Am J Respir Cell Mol Biol (2011) 0.93
Effects of altered plasminogen activator inhibitor-1 expression on cardiovascular disease. Curr Drug Targets (2011) 0.93
Therapeutic targets in systemic sclerosis. Arthritis Res Ther (2007) 0.91
Towards an anti-fibrotic therapy for scleroderma: targeting myofibroblast differentiation and recruitment. Fibrogenesis Tissue Repair (2010) 0.90
Pathogenesis of Systemic Sclerosis. Front Immunol (2015) 0.89
Transforming growth factor-β1 downregulates vascular endothelial growth factor-D expression in human lung fibroblasts via the Jun NH2-terminal kinase signaling pathway. Mol Med (2014) 0.89
Possible strategies for anti-fibrotic drug intervention in scleroderma. J Cell Commun Signal (2011) 0.89
Tumor necrosis factor α stimulates endothelin-1 synthesis in rat hepatic stellate cells in hepatic wound healing through a novel IKK/JNK pathway. Exp Cell Res (2011) 0.87
Transforming growth factor-β regulates endothelin-1 signaling in the newborn mouse lung during hypoxia exposure. Am J Physiol Lung Cell Mol Physiol (2012) 0.87
alpha2-antiplasmin is associated with the progression of fibrosis. Am J Pathol (2009) 0.84
Combination of roflumilast with a beta-2 adrenergic receptor agonist inhibits proinflammatory and profibrotic mediator release from human lung fibroblasts. Respir Res (2012) 0.83
Differential and synergistic effects of mechanical stimulation and growth factor presentation on vascular wall function. Biomaterials (2013) 0.83
Bosentan reverses the pro-fibrotic phenotype of systemic sclerosis dermal fibroblasts via increasing DNA binding ability of transcription factor Fli1. Arthritis Res Ther (2014) 0.83
Plasma endothelin-1 and vascular endothelial growth factor levels and their relationship to hemodynamics in idiopathic pulmonary fibrosis. Respiration (2012) 0.83
Blockade of endothelinergic receptors prevents development of proliferative vitreoretinopathy in mice. Am J Pathol (2008) 0.82
Reduced granulation tissue and wound strength in the absence of α11β1 integrin. J Invest Dermatol (2015) 0.81
Endothelin Receptors Expressed by Immune Cells Are Involved in Modulation of Inflammation and in Fibrosis: Relevance to the Pathogenesis of Systemic Sclerosis. J Immunol Res (2015) 0.80
α2AP mediated myofibroblast formation and the development of renal fibrosis in unilateral ureteral obstruction. Sci Rep (2014) 0.79
A pathogenetic role for endothelin-1 in peritoneal dialysis-associated fibrosis. J Am Soc Nephrol (2014) 0.79
Macitentan inhibits the transforming growth factor-β profibrotic action, blocking the signaling mediated by the ETR/TβRI complex in systemic sclerosis dermal fibroblasts. Arthritis Res Ther (2015) 0.79
Lymphomagenic CARD11/BCL10/MALT1 signaling drives malignant B-cell proliferation via cooperative NF-κB and JNK activation. Proc Natl Acad Sci U S A (2015) 0.78
Ca(2+) and ion channels in hypoxia-mediated pulmonary hypertension. Int J Clin Exp Pathol (2015) 0.78
Kinase-dependent activation of voltage-gated Ca2+ channels by ET-1 in pulmonary arterial myocytes during chronic hypoxia. Am J Physiol Lung Cell Mol Physiol (2012) 0.78
Getting out of a sticky situation: targeting the myofibroblast in scleroderma. Open Rheumatol J (2012) 0.77
Transforming growth factor-β inhibition and endothelin receptor blockade in rats with monocrotaline-induced pulmonary hypertension. Pulm Circ (2012) 0.76
Transforming growth factor-beta does not induce endothelin-1 secretion in primary cultured human tenon's fibroblasts. Korean J Ophthalmol (2008) 0.75
Elevated blood plasma levels of epinephrine, norepinephrine, tyrosine hydroxylase, TGFβ1, and TNFα associated with high-altitude pulmonary edema in an Indian population. Ther Clin Risk Manag (2016) 0.75
Bosentan and macitentan prevent the endothelial-to-mesenchymal transition (EndoMT) in systemic sclerosis: in vitro study. Arthritis Res Ther (2016) 0.75
Correlation between congenital heart disease complicated with pulmonary artery hypertension and circulating endothelial cells as well as endothelin-1. Int J Clin Exp Pathol (2015) 0.75
Immunohistochemical Localization of Epithelial Mesenchymal Transition Markers in Cyclosporine A Induced Gingival Overgrowth. J Clin Diagn Res (2016) 0.75
Evaluation of urinary bladder fibrogenesis in a mouse model of long-term ketamine injection. Mol Med Rep (2016) 0.75
Reducing Cardiac Fibrosis: Na/K-ATPase Signaling Complex as a Novel Target. Cardiovasc Pharm Open Access (2017) 0.75
Olodaterol Shows Anti-Fibrotic Efficacy in in vitro and in vivo Models of Pulmonary Fibrosis. Br J Pharmacol (2017) 0.75
Myofibroblasts and mechano-regulation of connective tissue remodelling. Nat Rev Mol Cell Biol (2002) 14.80
TGF-beta signaling and the fibrotic response. FASEB J (2004) 9.81
SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7. Mol Pharmacol (2002) 8.89
Identification of Smad7, a TGFbeta-inducible antagonist of TGF-beta signalling. Nature (1997) 7.69
Production of a tissue-like structure by contraction of collagen lattices by human fibroblasts of different proliferative potential in vitro. Proc Natl Acad Sci U S A (1979) 6.09
TAK1, but not TAB1 or TAB2, plays an essential role in multiple signaling pathways in vivo. Genes Dev (2005) 5.56
Fibroblasts, myofibroblasts, and wound contraction. J Cell Biol (1994) 4.60
CTGF and SMADs, maintenance of scleroderma phenotype is independent of SMAD signaling. J Biol Chem (2001) 3.28
Interleukin 1 (IL-1) gene expression, synthesis, and effect of specific IL-1 receptor blockade in rabbit immune complex colitis. J Clin Invest (1990) 2.86
Functional characterization of transforming growth factor beta signaling in Smad2- and Smad3-deficient fibroblasts. J Biol Chem (2001) 2.85
Role and interaction of connective tissue growth factor with transforming growth factor-beta in persistent fibrosis: A mouse fibrosis model. J Cell Physiol (1999) 2.77
Structural basis for the selective inhibition of JNK1 by the scaffolding protein JIP1 and SP600125. EMBO J (2004) 2.53
Connective tissue growth factor gene regulation. Requirements for its induction by transforming growth factor-beta 2 in fibroblasts. J Biol Chem (2003) 2.35
The extracellular matrix as a scaffold for tissue reconstruction. Semin Cell Dev Biol (2002) 2.31
Endothelin-1 promotes myofibroblast induction through the ETA receptor via a rac/phosphoinositide 3-kinase/Akt-dependent pathway and is essential for the enhanced contractile phenotype of fibrotic fibroblasts. Mol Biol Cell (2004) 2.29
Expression and regulation of intracellular SMAD signaling in scleroderma skin fibroblasts. Arthritis Rheum (2003) 2.20
Factors influencing myofibroblast differentiation during wound healing and fibrosis. Cell Biol Int (1995) 1.86
Clinical deterioration in patients with idiopathic pulmonary fibrosis: causes and assessment. Am J Med (1990) 1.83
CCN2 (connective tissue growth factor) promotes fibroblast adhesion to fibronectin. Mol Biol Cell (2004) 1.83
Mechanism of action of a dominant-negative mutant of c-Jun. Oncogene (1994) 1.81
CTGF expression in mesangial cells: involvement of SMADs, MAP kinase, and PKC. Kidney Int (2002) 1.77
Targeted disruption of TGF-beta/Smad3 signaling modulates skin fibrosis in a mouse model of scleroderma. Am J Pathol (2004) 1.77
Tumor necrosis factor alpha suppresses the induction of connective tissue growth factor by transforming growth factor-beta in normal and scleroderma fibroblasts. J Biol Chem (2000) 1.74
Prostacyclin derivatives prevent the fibrotic response to TGF-beta by inhibiting the Ras/MEK/ERK pathway. FASEB J (2002) 1.64
Transforming growth factor-beta and connective tissue growth factor: key cytokines in scleroderma pathogenesis. Curr Opin Rheumatol (2001) 1.55
Transforming growth Factor-beta1 induces phenotypic modulation of human lung fibroblasts to myofibroblast through a c-Jun-NH2-terminal kinase-dependent pathway. Am J Respir Crit Care Med (2001) 1.52
Endothelin-1 induces expression of matrix-associated genes in lung fibroblasts through MEK/ERK. J Biol Chem (2004) 1.52
Fibroblast matrix gene expression and connective tissue remodeling: role of endothelin-1. J Invest Dermatol (2001) 1.51
Smad3/AP-1 interactions control transcriptional responses to TGF-beta in a promoter-specific manner. Oncogene (2001) 1.51
Increased levels of endothelin-1 and differential endothelin type A and B receptor expression in scleroderma-associated fibrotic lung disease. Am J Pathol (1997) 1.47
The comparative role of activator protein 1 and Smad factors in the regulation of Timp-1 and MMP-1 gene expression by transforming growth factor-beta 1. J Biol Chem (2003) 1.45
Pathogenesis of scleroderma. Collagen. Rheum Dis Clin North Am (1996) 1.39
Molecular pharmacology of endothelin converting enzymes. Biochem Pharmacol (1996) 1.39
Elevated levels of platelet derived growth factor and transforming growth factor-beta 1 in bronchoalveolar lavage fluid from patients with scleroderma. J Rheumatol (1995) 1.38
Significance of plasma endothelin-1 levels in patients with systemic sclerosis. J Rheumatol (1992) 1.32
Impaired Smad7-Smurf-mediated negative regulation of TGF-beta signaling in scleroderma fibroblasts. J Clin Invest (2004) 1.32
Endothelins. FASEB J (1991) 1.31
Contribution of activin receptor-like kinase 5 (transforming growth factor beta receptor type I) signaling to the fibrotic phenotype of scleroderma fibroblasts. Arthritis Rheum (2006) 1.30
Functional cooperation between Smad proteins and activator protein-1 regulates transforming growth factor-beta-mediated induction of endothelin-1 expression. Circ Res (2003) 1.27
Purification and characterization of a phosphoramidon-sensitive endothelin-converting enzyme in porcine aortic endothelium. OFF. J Biol Chem (1993) 1.20
Localisation of transforming growth factor beta1 and beta3 mRNA transcripts in normal and fibrotic human lung. Thorax (2001) 1.18
Dissecting the roles of endothelin, TGF-beta and GM-CSF on myofibroblast differentiation by keratinocytes. Thromb Haemost (2004) 1.15
Cell-specific induction of distinct oncogenes of the Jun family is responsible for differential regulation of collagenase gene expression by transforming growth factor-beta in fibroblasts and keratinocytes. J Biol Chem (1996) 1.13
Stable expression of a c-JUN deletion mutant in two malignant mouse epidermal cell lines blocks tumor formation in nude mice. Cell Growth Differ (1994) 1.12
The JNK-interacting protein-1 scaffold protein targets MAPK phosphatase-7 to dephosphorylate JNK. J Biol Chem (2003) 1.10
A central role for the JNK pathway in mediating the antagonistic activity of pro-inflammatory cytokines against transforming growth factor-beta-driven SMAD3/4-specific gene expression. J Biol Chem (2002) 1.08
Cell and molecular regulation of endothelin-1 production during hepatic wound healing. Mol Biol Cell (2003) 1.05
Increased endothelin-1 production in fibroblasts derived from patients with systemic sclerosis. Ann Rheum Dis (1994) 1.03
A cytokine reborn? Endothelin-1 in pulmonary inflammation and fibrosis. Am J Respir Cell Mol Biol (2000) 1.03
Role of connective tissue proteases in the pathogenesis of chronic inflammatory lung disease. Environ Health Perspect (1984) 1.02
Pulmonary fibrosis: cellular and molecular events. Pathol Int (2003) 0.96
Selective tyrosine kinase inhibitor for the platelet-derived growth factor receptor in vitro inhibits smooth muscle cell proliferation after reinjury of arterial intima in vivo. Cardiovasc Drugs Ther (1999) 0.96
Binding characteristics and vascular effects of various angiotensin II antagonists. J Cardiovasc Pharmacol (1990) 0.95
Impaired regulation of collagen pro-alpha 1(I) mRNA and change in pattern of collagen-binding integrins on scleroderma fibroblasts. J Invest Dermatol (1993) 0.95
Scleroderma lung fibroblasts exhibit elevated and dysregulated type I collagen biosynthesis. Arthritis Rheum (1997) 0.92
Endothelins. Blood Vessels (1990) 0.85
Induction of subcutaneous tissue fibrosis in newborn mice by transforming growth factor beta--simultaneous application with basic fibroblast growth factor causes persistent fibrosis. Biochem Biophys Res Commun (1997) 0.84
Collagen synthesis and degradation by systemic sclerosis lung fibroblasts. Responses to transforming growth factor-beta. Chest (1991) 0.82
Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol (2009) 12.05
Bosentan therapy for pulmonary arterial hypertension. N Engl J Med (2002) 11.18
Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med (2014) 10.62
TGF-beta signaling and the fibrotic response. FASEB J (2004) 9.81
A common MUC5B promoter polymorphism and pulmonary fibrosis. N Engl J Med (2011) 6.40
A myocardial lineage derives from Tbx18 epicardial cells. Nature (2008) 6.15
2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum (2013) 5.99
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet (2011) 5.94
Induction of epithelial-mesenchymal transition in alveolar epithelial cells by transforming growth factor-beta1: potential role in idiopathic pulmonary fibrosis. Am J Pathol (2005) 5.88
An official American Thoracic Society clinical practice guideline: the clinical utility of bronchoalveolar lavage cellular analysis in interstitial lung disease. Am J Respir Crit Care Med (2012) 5.37
All in the CCN family: essential matricellular signaling modulators emerge from the bunker. J Cell Sci (2006) 5.18
Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society project. Am J Respir Crit Care Med (2008) 3.97
Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med (2011) 3.85
Sarcoidosis. Lancet (2003) 3.60
BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2007) 3.49
A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum (2006) 3.45
BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2011) 3.23
Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial. Lancet (2009) 3.21
Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med (2008) 3.19
Genome-wide association study identifies multiple susceptibility loci for pulmonary fibrosis. Nat Genet (2013) 3.17
2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. Ann Rheum Dis (2013) 3.11
Fibrotic idiopathic interstitial pneumonia: the prognostic value of longitudinal functional trends. Am J Respir Crit Care Med (2003) 3.07
Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med (2002) 3.06
A polymorphism in the CTGF promoter region associated with systemic sclerosis. N Engl J Med (2007) 2.95
Recombinant human anti-transforming growth factor beta1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192. Arthritis Rheum (2007) 2.80
Idiopathic pulmonary fibrosis: a composite physiologic index derived from disease extent observed by computed tomography. Am J Respir Crit Care Med (2003) 2.78
Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial. Am J Respir Crit Care Med (2008) 2.65
Identification of PLOD2 as telopeptide lysyl hydroxylase, an important enzyme in fibrosis. J Biol Chem (2003) 2.63
Connective tissue disease-associated interstitial lung disease: a call for clarification. Chest (2010) 2.51
Gene regulation of connective tissue growth factor: new targets for antifibrotic therapy? Matrix Biol (2002) 2.45
PGC-1alpha regulates the mitochondrial antioxidant defense system in vascular endothelial cells. Cardiovasc Res (2005) 2.43
Regulation and function of connective tissue growth factor/CCN2 in tissue repair, scarring and fibrosis. Cytokine Growth Factor Rev (2008) 2.40
Connective tissue growth factor gene regulation. Requirements for its induction by transforming growth factor-beta 2 in fibroblasts. J Biol Chem (2003) 2.35
Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. Ann Rheum Dis (2010) 2.30
Endothelin-1 promotes myofibroblast induction through the ETA receptor via a rac/phosphoinositide 3-kinase/Akt-dependent pathway and is essential for the enhanced contractile phenotype of fibrotic fibroblasts. Mol Biol Cell (2004) 2.29
The SF-36 and SGRQ: validity and first look at minimum important differences in IPF. Respir Med (2009) 2.18
Mucin 5B promoter polymorphism is associated with idiopathic pulmonary fibrosis but not with development of lung fibrosis in systemic sclerosis or sarcoidosis. Thorax (2013) 2.17
Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertension. Eur Heart J (2006) 2.16
Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia: an under-recognised spectrum of disease. Thorax (2006) 2.10
Efficacy of the specific endothelin a receptor antagonist zibotentan (ZD4054) in colorectal cancer: a preclinical study. Mol Cancer Ther (2013) 2.05
CCN2 is necessary for adhesive responses to transforming growth factor-beta1 in embryonic fibroblasts. J Biol Chem (2006) 1.96
Prognostic implications of histologic patterns in multiple surgical lung biopsies from patients with idiopathic interstitial pneumonias. Chest (2004) 1.95
Inducible lineage-specific deletion of TbetaRII in fibroblasts defines a pivotal regulatory role during adult skin wound healing. J Invest Dermatol (2008) 1.92
All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials. Am J Respir Crit Care Med (2014) 1.89
CCN2 (connective tissue growth factor) promotes fibroblast adhesion to fibronectin. Mol Biol Cell (2004) 1.83
Shared expression of phenotypic markers in systemic sclerosis indicates a convergence of pericytes and fibroblasts to a myofibroblast lineage in fibrosis. Arthritis Res Ther (2005) 1.81
Identification of novel genetic markers associated with clinical phenotypes of systemic sclerosis through a genome-wide association strategy. PLoS Genet (2011) 1.80
The role of connective tissue growth factor, a multifunctional matricellular protein, in fibroblast biology. Biochem Cell Biol (2003) 1.80
The relationship between individual histologic features and disease progression in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2002) 1.80
CTGF expression in mesangial cells: involvement of SMADs, MAP kinase, and PKC. Kidney Int (2002) 1.77
S-nitrosylation of Hsp90 promotes the inhibition of its ATPase and endothelial nitric oxide synthase regulatory activities. Proc Natl Acad Sci U S A (2005) 1.77
An essential role for resident fibroblasts in experimental lung fibrosis is defined by lineage-specific deletion of high-affinity type II transforming growth factor β receptor. Am J Respir Crit Care Med (2010) 1.76
Mechanisms and consequences of fibrosis in systemic sclerosis. Nat Clin Pract Rheumatol (2006) 1.73
Flexibility and diversity in consultant careers. Clin Med (2002) 1.71
Platelet-derived growth factor-beta receptor activation is essential for fibroblast and pericyte recruitment during cutaneous wound healing. Am J Pathol (2006) 1.70
Ligand-dependent genetic recombination in fibroblasts : a potentially powerful technique for investigating gene function in fibrosis. Am J Pathol (2002) 1.68
Pivotal role of connective tissue growth factor in lung fibrosis: MAPK-dependent transcriptional activation of type I collagen. Arthritis Rheum (2009) 1.65
Selective expression of connective tissue growth factor in fibroblasts in vivo promotes systemic tissue fibrosis. Arthritis Rheum (2010) 1.64
Prostacyclin derivatives prevent the fibrotic response to TGF-beta by inhibiting the Ras/MEK/ERK pathway. FASEB J (2002) 1.64